Second Cancers and Immunotherapy — What Is Known, and What Is Not Yet

Is There an Increased Risk of a Second Cancer After Immunotherapy?

There is no established evidence that checkpoint inhibitors themselves cause second cancers. They do not damage DNA the way radiotherapy and some chemotherapy drugs do. But these drugs have only been in wide clinical use since the mid-2010s, so nobody can yet speak about decades. That gap is real, and it is worth saying out loud.

The question usually arrives late. Treatment is over, the scans have been stable for a while, life has restarted — and then somebody mentions that cancer treatment can cause cancer. For people who thought they were finished, that lands hard. The useful first move is to separate three things that get called the same thing in ordinary conversation, because only one of them is what this page is about.

Only the third row is what “second cancer” means here. The distinction is made on tissue, not on a scan report, and it changes the entire treatment plan — which is why a new finding is biopsied rather than assumed either way.

What Does the Data Show About Second Cancers After Immunotherapy?

Less than people assume. Long-term second-cancer risk is documented in detail after radiotherapy and after certain chemotherapy classes. For checkpoint inhibitors the follow-up is short, most patients also received other treatment, and no major guideline body currently attributes a second-cancer risk to them. Immature is the accurate word.

It helps to see where the established associations actually sit, because most of what is written about treatment-related second cancers predates immunotherapy entirely and describes drugs and doses that work in a completely different way.

Source: this reflects how NCCN, ASCO and ESMO survivorship guidance describes the recognised second-cancer associations of cancer treatment. How much any of it applies to one person depends on dose, field, age at treatment and the cancer being treated, which is why the specifics belong in a conversation about your own records rather than on a web page.

Why Is the Honest Answer Still “We Do Not Know Yet”?

Four reasons, and none of them is evasion. Wide clinical use of these drugs began around the mid-2010s. Most patients received them alongside other treatment. Cancer survivors are scanned more, so more gets found. And the biology cuts both ways. A confident long-term figure would be going past the evidence.

• The follow-up is short. Modern checkpoint inhibitors entered wide clinical use from the early-to-mid 2010s. A twenty-year question cannot be settled with roughly ten years of observation.
• Attribution is tangled. Most people who receive immunotherapy also have surgery, radiation or chemotherapy. Separating what one drug did from what the rest of the treatment did is difficult by design.
• Survivors are watched more closely. People under surveillance have more imaging and more blood tests than the general population, so unrelated cancers are found earlier and more often. That is detection, not causation.
• The biology is not one-directional. These drugs release a brake on immune cells rather than damaging DNA. What sustained immune modulation means across decades is still being studied.
• Saying so is the credible position. Where guidance is silent, the accurate answer is that the evidence is still emerging — which is not the same as claiming the risk is zero, and not the same as implying it is high.

The same honesty applies across this part of survivorship. Long-term immune-related effects, fertility and late organ changes are all areas where the evidence is younger than the questions — the broader picture is set out in long-term side effects of immunotherapy. Nothing on this page is a prognosis, and none of it predicts what will happen to you.

What Screening Should I Have After Immunotherapy?

Three layers, all decided by your treating team. The routine screening that applies to any adult your age. Surveillance for the cancer you were treated for, on the interval your oncologist sets. And anything your treatment history adds, such as blood counts after certain chemotherapy or attention to a treated radiation field.

1. 1

   Routine screening still applies to you

   Having had cancer does not remove you from ordinary screening. Ask which national recommendations apply at your age and sex, because these are the checks most often dropped once someone is “an oncology patient”.

2. 2

   Surveillance for the cancer you were treated for

   Your oncologist sets the visits, blood tests and imaging from your own records. This is clinician-directed and it is revised at each review, not fixed for life.

3. 3

   Anything your treatment history adds

   Radiation, alkylating chemotherapy or a long steroid course each leave their own follow-up behind — the steroid side of that is covered in bone health and long steroid exposure.

4. 4

   Your own risk factors, written down

   Family history, an inherited syndrome, tobacco, alcohol and HPV-related disease shape second-cancer risk far more than immunotherapy does. Ask whether genetic counselling belongs in your plan.

5. 5

   One list, with a named owner per test

   Ask for the schedule in writing with the person responsible for each item. Monitoring lapses most often at the handover from oncology to your family physician, when everyone assumes someone else is ordering it.

At CION, immunotherapy is given as a day-care infusion and the same medical oncology team reviews you afterwards; response-assessment imaging such as PET-CT is coordinated at partner imaging centres rather than owned by us. The visit-by-visit shape of the early years is set out in your follow-up schedule after immunotherapy, and infection and vaccination questions that sit alongside screening are covered in vaccination and infection risk in long-term survivors.

Which Symptoms Should Send Me Back to My Doctor?

Anything new that persists past two or three weeks without an obvious explanation. A new lump, unexplained weight loss, unusual bleeding, a persistent cough or hoarse voice, a lasting change in bowel habit, or a mole that changes. Report it rather than waiting for the next scheduled visit.

None of these means a second cancer. Most turn out to be something else entirely, and saying that plainly matters as much as the list itself. The reason to report them is that surveillance only works when the gaps between visits are covered by you.

• Persistent and unexplained is the pattern. A symptom that lasts, without a clear cause, is worth a look. A symptom that came and went in three days usually is not.
• Recent immunotherapy changes the reading. Some symptoms can be immune-related side effects rather than anything new, and they can begin months after the last dose — another reason to be assessed rather than to decide yourself.
• Say the drug and the date early. Any doctor seeing you needs the immunotherapy name and the date of your last dose near the start of the conversation, not after the tests come back.
• Paperwork keeps asking too. Insurance renewals and employment forms will want the same history for years — what to disclose and when is covered in insurance and employment after immunotherapy.
• Keep it on one page. Diagnosis, drug, cycles, last dose, side effects and current medicines belong in a written survivorship care plan you can hand to any doctor.

If something new appears and you are not sure who to call, our oncology team can be reached on 1800 202 8726. Assessment of a new symptom is clinician-directed and is based on your own records, not on a general list.

Where People Usually Read Next

Second cancers are one of a small cluster of questions that surface long after the infusions stop — alongside vaccination, bone health after steroids, and the paperwork that keeps asking about your history. For the general picture of how the treatment itself is given and reviewed, start at immunotherapy at CION Cancer Clinics.

An Honest Answer Beats a Confident One

Where the evidence is still emerging we say so — and then we set out what screening applies to you and who is responsible for it.